Use of Sacral Neuromodulation in the Management of ... - SUNA
Use of Sacral Neuromodulation in the Management of ... - SUNA Use of Sacral Neuromodulation in the Management of ... - SUNA
Urinary Urgency-frequency and Urinary Urge Incontinence 1. Stewart WF, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003:20:327-336. 2. Garnett S, et al. The natural history of overactive bladder and detrusor overactivity: a review of evidence regarding the long-term outcome of the overactive bladder. J Urol. 2003;169:843. 3. Haab F, et al. Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract. 2005;59(8): 931-937. Ziment Market Research 2005. 4. Medtronic Market Research 1998 US prevalence = 33.3 million 1 7.3 million Women: 2.9 million Men: 1.1 million Women: 2.0 million Men: 0.8 million Total: 1.8 million Women: 1.3 million Men: 0.5 million 16.5% of US population 1 30% actively seeking care (excluding men w/BPH ~8.0 million) 2 Patients who cannot tolerate pharmacotherapy (~55%) 4.0 million 3 Patients with continued symptoms actively seeking further treatment (~70%) 4 2.8 million Potential patient candidates for SNS † (~65%)* Net Prevalence @ 1.8 million * Assuming clinical exclusion of 20% & economic exclusion of 15%
Overview Sacral Nerve Stimulation (SNS)
- Page 1 and 2: Use of Sacral Neuromodulation in th
- Page 3 and 4: Program Goal To discuss the prevale
- Page 5 and 6: Voiding Dysfunction: A Hidden Probl
- Page 7 and 8: Filling Phase • Automatic Actions
- Page 9: Abnormal Micturition Voiding dysfun
- Page 13 and 14: SNS - Therapy SNS utilizes mild ele
- Page 15 and 16: Pharmacotherapy vs. SNS Therapy Pha
- Page 17 and 18: 5-Year Clinical Efficacy Urge Incon
- Page 19 and 20: 5-Year Clinical Efficacy Urinary Re
- Page 21 and 22: Treatment Algorithm For Urinary Urg
- Page 23 and 24: Other Issues Influencing Patient Se
- Page 25 and 26: Test & Implant Procedures • 1 st
- Page 27 and 28: Voiding Diary Documentation 3 days
- Page 29 and 30: 2 nd Stage Implant Procedure 2 nd S
- Page 31 and 32: Benefits of SNS Potential Adverse E
- Page 33 and 34: Case Studies Retention with frequen
- Page 35 and 36: Voiding Diary • Pt voids 2-4 oz q
- Page 37 and 38: Strains to Void
- Page 39 and 40: Urodynamic Results • Normal stora
- Page 41 and 42: Post InterStim Implant • Doing ex
- Page 43 and 44: Utilization of Multiple Modalities
- Page 45 and 46: Management of Care • Life choices
- Page 47 and 48: Summary • SNS is an effective tre
- Page 49 and 50: Revision for SUNA Oct 2010 - Lisa Z
Overview<br />
<strong>Sacral</strong> Nerve Stimulation (SNS)
Change language